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Abstract 
Rational: N-methyl-D-aspartate receptor (NMDA-R) hypofunction has been proposed 
to account for the pathophysiology of schizophrenia. Thus, NMDA-R blockade has 
been used to model schizophrenia in experimental animals. Acute and repeated 
treatments have been successfully tested; however, long-term exposure to NMDA-R 
antagonists more likely resembles the core symptoms of the illness.  
Objectives: to explore whether schizophrenia-related behaviors are differentially 
induced by acute and subchronic PCP treatment in mice, and to examine the 
neurobiological bases of these differences. 
Results: Subchronic PCP induced a sensitization of acute locomotor effects. 
Spontaneous alternation in a T-maze and novel object recognition performance were 
impaired after subchronic but not acute PCP, suggesting a deficit in working memory. 
On the contrary, reversal learning and immobility in the tail suspension test were 
unaffected. Subchronic PCP significantly reduced basal dopamine but not serotonin 
output in mPFC, and markedly decreased the expression of tyrosine hydroxylase in the 
ventral tegmental area. Finally, acute and subchronic PCP treatments evoked a different 
pattern of c-fos expression. At 1h post-treatment, acute PCP increased c-fos expression 
in many cortical regions, striatum, thalamus, hippocampus and dorsal raphe. However, 
the increased c-fos expression produced by subchronic PCP was restricted to the 
retrosplenial cortex, thalamus, hippocampus and supramammillary nucleus. Four days 
after the last PCP injection, c-fos expression was still increased in the hippocampus of 
subchronic PCP-treated mice.  
Conclusions: Acute and subchronic PCP administration differently affects neuronal 
activity in brain regions relevant to schizophrenia, which could account for their 
different behavioral effects.   
 
Keywords: behavior, c-fos, dopamine, phencyclidine, glutamate, NMDA, serotonin, 
schizophrenia, reversal learning, working memory. 
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Introduction  
Compelling evidence supports a deficient glutamate-mediated excitatory 
neurotransmission through NMDA glutamate receptors (NMDA-R) in schizophrenia 
(Coyle et al. 2003; Coyle 2006; Moghaddam and Javitt 2012). NMDA-R hypofunction 
hypothesis stemmed from the clinical observation that sub-anesthetic doses of non-
competitive NMDA-R antagonists such as phencyclidine (PCP) and ketamine induced 
psychotic reactions in healthy individuals and exacerbated the symptomatology in 
schizophrenic patients (Coyle, 2006; Javitt and Zukin 1991; Krystal et al. 1994; Luby et 
al. 1959). Thereafter, NMDA-R blockade in rodents was proposed as an animal model 
of the disease (Kantrowitz and Javitt 2010; Krystal et al. 2003, Neill et al. 2010; Jones 
et al. 2011). Rodent models of schizophrenia are very useful in preclinical neuroscience 
research and in antipsychotic drug development. However, they have obvious 
limitations due to the unknown etiology of the disease, the high inter-individual 
symptom variability and the inability to reproduce subjective symptoms of the illness. 
Therefore, current animal models of schizophrenia are intended to assess specific 
endophenotypes instead of modeling the disease as a whole (Amann et al. 2010; 
Kaffman and Krystal 2012; Robbins 2012).The identification of rodent endophenotypes 
represents a critical step to elucidate the neurobiological basis of the deficits and the 
development of new treatment strategies.  
Non-competitive NMDA-R antagonists such as PCP, ketamine and dizolcipine 
(MK-801) have been very effective in triggering schizophrenia-like positive symptoms, 
negative symptoms and cognitive deficits in rodents (Bondi et al. 2012; Frohlich and 
Van Horn 2014; Neill et al. 2010). However, behavioral manifestations induced by 
NMDA-R antagonists seem particularly dependent on pharmacological and procedural 
features, which difficult the clarification of their neural underlying mechanisms. Hence, 
there is evidence for drug specific disturbances (Dix et al, 2010; Seillier and Giuffrida 
2009). As an example, withdrawal from subchronic PCP but not MK-801 caused a 
delay-dependent impairment of working memory, reduced social interaction and 
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enhanced d-amphetamine-induced motor activity (Seillier and Giuffrida 2009), 
suggesting that other mechanisms apart from NMDA-R blockade may contribute to 
behavioral effects of NMDA-R antagonists.  
Once restricted to a certain drug, other factors such as the age of the subjects, the 
strain, the dose, and the duration of the treatments do also account. Age appears to be a 
key factor, since differential behavioral effects have been observed after NMDA-R 
antagonist administration to young or adult subjects, possibly due to differential brain 
NMDA-R subunit composition along the lifetime and the distinct biophysical, 
pharmacological and signaling properties of each receptor subtype (Paoletti et al. 2013). 
Strain differences have also been described for PCP-induced hyperlocomotion and 
immobility responses in the forced swim test (Mouri et al. 2012; Van den Buuse 2010). 
Moreover, the effects of non-competitive NMDA-R antagonists are clearly dose-
dependent (Hiyoshi et al. 2014; Van den Buuse 2010). Finally, treatment duration also 
impacts on the behavioral phenotype caused by NMDA-R blockade, and several studies 
suggested that chronic treatments produce more robust and long-lasting effects than 
acute drug treatments (Egerton et al. 2008; Jentsch and Roth 1999; Neill et al. 2014; 
Spielewoy and Markou 2003; Thomson et al. 2011). In this context of high 
pharmacological and methodological variability using NMDA-R antagonists, 
standardization studies are a pre-requisite to further explore the cellular, and network 
elements involved in their behavioral effects. The aim of the present study was to 
evaluate the possible differential behavioral effects of acute and subchronic PCP 
treatment in adult C57BL6/J mice, to further explore their underlying neurobiological 
bases using neurochemical and histological techniques.   
Materials and methods 
Subjects 
We used 8-12 week-old male C57BL/6J mice (Charles River, France). Animals were 
group-housed five per cage and kept in a controlled environment (12 h light–dark cycle 
and 22±2°C room temperature) with food and water provided ad-libitum. Mice 
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underwent the reversal learning task were individually housed and food-restricted as 
described below. Animal experiments followed the Principles of laboratory animal care 
and the Guidelines for care and use of mammals in neuroscience and behavioral 
Research (National Research Council 2003). All experimental procedures were in strict 
accordance with European Union regulations (2010/63 UE, 22
nd
 September 2010), and 
were approved by the Institutional Animal Care and Use Committee. 
Drugs and treatments 
Phencyclidine hydrochloride (Sigma-Aldrich, UK) was dissolved in physiological 
saline, pH adjusted to 6.5-7.0 and administered by subcutaneous route (s.c.). The 
volume of injection was 10 ml/kg. Doses are expressed as free base. 
Mice were administered PCP or saline for 10 days (once daily on days 1–5, 8–
12) as previously described Hashimoto et al. (2005). This treatment regime has been 
previously shown to induce long-lasting memory deficits in the NOR in mice, that are 
reversed by antipsychotic drugs (Tanibuchi et al. 2009). Three experimental groups 
were used: subchronic, acute and control. Mice on the subchronic group received PCP 
(10 mg/kg, s.c., 10 days). Mice in the acute group received saline (10 ml/kg, s.c., 9 
days) and PCP on the last day of treatment (10 mg/kg, s.c., day 12). Control mice 
received saline (10 ml/kg, s.c., 10 days). 
 All efforts were made to ensure that the experimenter was blind to treatment 
conditions during scoring of the behavioral tests. 
Locomotor activity measurements 
Distance moved (cm) in an open-field was used as a measure of locomotor activity. The 
open-field (30 x 30 cm) was made of black plastic and dimly illuminated (30-40 lux). 
Locomotor activity measurements were performed on days 1 and 12, and started 10 min 
after drug administration. Data were collected in 5-min bins by the videotrack system 
software (Viewpoint, France) during 90 min.   
Spontaneous alternation and Novel object recognition in a T-maze 
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On withdrawal day 4 (WD4), mice were habituated for 10 min to the T-maze (Panlab, 
Barcelona) and spontaneous alternation was measured. The spontaneous alternation task 
is used to assess spatial working memory in rodents and is based on the innate tendency 
of rodents to explore a prior unexplored arm of a maze. Alternation was defined as 
successive entries into the three arms of the maze, on the overlapping triplet sets. The 
percentage alternation was calculated as the ratio of actual to possible alternations as 
previously reported (Hiramatsu et al. 1997). Twenty-four hours later (withdrawal day 5, 
WD5), mice were put back in the maze for 10 min where two identical objects were 
presented (T1), one in each lateral arm end, and the time the animals spent exploring 
each object was recorded. Three min later (T2), mice were put again in the maze for 10 
min, where one of the familiar objects was replaced by a novel object (in a 
counterbalanced way), and the total time spent exploring each of the two objects (novel 
and familiar) was computed. Object exploration was defined as the orientation of the 
nose to the object at a distance < 1 cm. A recognition index (RI) was calculated as the 
percentage of the time exploring the novel object divided by the total time exploring the 
two objects (novel and familiar) as described [RI = N/(F+N) * 100]. RI > 50 % is 
considered to reflect greater memory retention for the familiar object. 
Tail suspension test 
On withdrawal day 7 (WD7) mice were tested in the tail suspension test (TST). TST 
was conducted essentially as described by Steru et al. (1985). Briefly, mice were 
suspended 30 cm above the floor by adhesive tape placed approximately 1 cm from the 
tip of the tail and were observed on a monitor through a video camera system (Smart, 
Panlab). The time mice spent immobile (s) was recorded during 6 min.  
Reversal learning paradigm 
A different set of animals was used for the reversal learning testing. Prior to the 
beginning of training, mice were handled daily for three days, individually housed and 
put on a food-restriction schedule (to attain an 80% of free-feeding body weight). Water 
was available ad-libitum. The procedure was conducted in a T-maze (Panlab, 
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Barcelona) and consisted of different phases (see a schematic representation of the 
training and testing protocol in the Results section). Pre-training: all mice were initially 
familiarized with the testing apparatus during a 10-min day session. The next day, mice 
were adapted to consume food rewards (Grain-based rodent tablets 5TUM, TestDiet, 
Zurich) in the maze. Initially, 10 food pellets were placed in the maze and mice were 
trained in 10-min day sessions till criterion of ≥ 8 pellets eaten. Once criterion achieved, 
the food pellets were placed at the end of the goal-arms and the same criterion was 
applied. Discrimination: after habituation, mice were trained to turn right or left in the 
T-maze in order to get a food reward. Animals received one 10-trials session per day 
and were trained to a criterion of  ≥ 8 correct choices out of 10 in two consecutive days. 
Once the criterion on discrimination was reached, the pharmacological treatment 
started. Treatment: during the treatment with PCP (subchronic: 10 mg/kg, s.c., 10 days; 
acute: 10 ml/kg, s.c., 9 days plus 10 mg/kg, s.c., on day 12) or saline (10 ml/kg, s.c., 10 
days) mice were individually housed but no food-restriction was applied, thus they had 
free access to food and water ad-libitum. Re-discrimination: on withdrawal day 1 
(WD1), mice were put back to food-restriction conditions. Three days later, (WD4) re-
training on discrimination was performed with the same criteria as before. Reversal: in 
this phase, the rewarded egocentric response was reversed and mice received the food-
pellet after turning on the opposite direction as in discrimination and re-discrimination 
training. Animals received one 10-trials session per day and were trained to a criterion 
of ≥ 8 correct choices out of 10 in two consecutive days. Note that discrimination, re-
discrimination and reversal phases were performed in a drug-free state. The main 
measures of the animals’ ability to learn the discriminations/reversals were: (i) the 
number of total trials (TT) to criterion, and (ii) the number of incorrect trials (IT, errors) 
to criterion.  
Microdialysis experiments 
The effects of acute and subchronic PCP treatments on the extracellular serotonin (5-
HT) and dopamine (DA) levels in the medial PFC (mPFC) were measured by in vivo 
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microdialysis as previously described (Castañé et al. 2008). On day 11 of treatment, one 
concentric dialysis probe equipped with a Cuprophan membrane (2-mm long) was 
implanted in the mPFC at coordinates (in mm): AP+2.2; ML-0.2; DV-3.4 (Franklin and 
Paxinos, 1997), of anaesthetized mice (inhaled isofluorane carried in medical oxygen 
induced at 2.5% and maintained at 1.5 % concentrations at a rate of 0.6-0.7 L/min). 
Microdialysis experiments were performed 20-24 h after surgery on day 12 (the last day 
of treatment). For serotonin determinations, the aCSF was pumped at 2.0 µl/min (WPI 
model sp220i) and dialysates were collected every 30 min. Serotonin concentration in 
dialyzed samples was analyzed by HPLC with amperometric detection (Hewlett 
Packard 1049) at +0.6 V. For dopamine determinations, the aCSF containing 10 µM 
nomifensine was pumped at 1.65 µl/min (WPI model sp220i) and dialysates were 
collected every 20 min. In this case, brain dialysates were collected on micro vials 
containing 5 µl of 10 mM perchloric acid and dopamine concentration in dialyzed 
samples was analyzed by HPLC with amperometric detection (Hewlett Packard 1049) at 
+0.6 V. Following an initial 100-min stabilization period, four baseline samples were 
collected before the systemic drug administration, and then, successive dialysate 
samples were collected. Baseline serotonin and dopamine levels were calculated as the 
average of the four pre-drug samples. At the end of sample collection, brains were 
removed and sectioned to ensure proper probe placement after cresyl violet staining. 
In-situ hybridization and immunohistochemistry studies 
Immediate and late effects of PCP treatments on c-fos and tyrosine hydroxylase gene 
expression were examined by in-situ hybridization. Mice were sacrificed by cervical 
dislocation 1h or 96h (WD4) after the end of treatments. Animals processed at 96h 
received a saline injection 1h before the sacrifice. The brains were rapidly removed, 
frozen on dry ice, and stored at –30 ºC. Brain tissue sections, 14 mm thick, were cut 
using a microtome-cryostat (HM500 OM; Microm, Walldorf, Germany), thaw-mounted 
onto APTS (3-aminopropyltriethoxysilane, Sigma, St Louis, MO, USA)-coated slides 
and kept at – 30 ºC. c-fos oligonucleotide probe was complementary to bases 131-178 
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(GenBank ID:NM_022197). Tyrosine hydroxylase oligonucleotide probe was 
complementary to bases 1435-1474 (GenBank ID:NM_009377). Labeling of the probes 
([
33
P]-dATP (>2500 Ci/mmol); PerkinElmer NEN Radiochemicals, Boston, MA, USA), 
tissue sectioning and in-situ hybridization procedures were carried out as described 
(Kargieman et al. 2007; Santana et al. 2011). Hybridized sections were exposed to 
Biomax MR film (Kodak, Sigma-Aldrich, Madrid, Spain) for 7 days with intensifying 
screens. Relative optical densities (R.O.D.) were measured with the AIS computerized 
image analysis system (AIS, Imaging Research, St Catherines, Ontario, Canada). 
Individual values of optical densities were calculated as the mean of 2-4 sections per 
mice (n = 3 mice/group). NeuN immunohistochemistry: VTA neuronal integrity was 
evaluated by comparing number of VTA NeuN-positive cells in saline and subchronic 
PCP-treated animals sacrificed at 96h. 14µm-thick frozen brain tissue sections were 
processed for immunohistochemical visualization of NeuN by standard streptavidin-
biotin-peroxidase methodology using Anti-NeuN antibody (MAB377, Millipore, 
Madrid, Spain). 
Statistical analysis 
Data from spontaneous alternation, novel object recognition, tail suspension test, 
reversal learning, basal 5-HT and DA concentrations, TH and c-fos expression, and 
NeuN inmunolocalization were analyzed by a one-way ANOVA (treatment as between 
factor of variation).  Data from the locomotor activity and microdialysis experiments 
were analyzed by a two-way ANOVA with repeated measures (treatment as a between 
factor and time/fraction as within factor of variation). Significant main effects in the 
ANOVAs were further explored by post-hoc Newman-Keuls comparisons to establish 
simple effects. Data are given as mean ± SEM. Statistical significance was set at the 
95% confidence level. 
Results 
Locomotor activity effects induced by acute and subchronic PCP treatments 
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Subchronic PCP administration induced a sensitization of acute locomotor effects 
(Fig.1). Two-way ANOVA with repeated measures on day 1 showed a significant main 
effect of time [F(17, 272) = 12.30; p < 0.001], treatment [F(2,16) = 18.09; p < 0.001] and 
interaction between time and treatment [F(34, 272) = 8.96; p < 0.001]. Subsequent post-hoc 
Newman-Keuls comparisons showed a significant increase of the distance moved in the 
subchronic PCP group compared to the control group (p < 0.01). Two-way ANOVA 
with repeated measures on day 12 showed a significant main effect of time [F(17, 323) = 
4.46; p<0.001], treatment [F(2,19) = 26.28; p < 0.001] and interaction between time and 
treatment [F(34, 323) = 3.41; p<0.001]. Post-hoc Newman-Keuls comparisons showed a 
significant increase of distance moved in the subchronic and acute groups compared to 
the control group (p < 0.01, p < 0.05 respectively) and a significant difference between 
the subchronic and acute groups (p < 0.01) (Fig.1a). Similarly, two-way ANOVA with 
repeated measures on the accumulated distance data showed a significant main effect of 
day [F(1,16) = 19.42; p < 0.001], treatment [F(2,16) = 33.95; p<0.001] and interaction 
between day and treatment [F(2,16) = 7.43; p < 0.01]. Post-hoc Newman-Keuls 
comparisons showed a significant increase of total distance moved in the subchronic 
group compared to the control group (p < 0.01) on day 1, and a significant increase of 
total distance moved in the acute and subchronic groups compared to the control group 
(p < 0.05, p < 0.01, respectively) on day 12. Notably, on day 12 the total distance 
moved in the subchronic treated mice was significantly higher than in acute-treated 
mice (p < 0.01) (Fig.1b).  
Effects of acute and subchronic PCP treatments on working memory 
Subchronic but not acute PCP treatment induced working memory deficits in the 
spontaneous alternation (Fig.2a) and novel object recognition (Fig.2b) paradigms. One-
way ANOVA for the percentage of alternations in a T-maze showed a significant effect 
of treatment [F(2,18) = 5.91; p < 0.05]. Post-hoc Newman-Keuls comparisons showed a 
significant decrease of the percentage of alternations in the subchronic-treated mice 
compared to control (p < 0.05) and acute-treated (p < 0.05) mice (Fig.2a). One-way 
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ANOVA showed non-significant differences on the total number of arms visits in the 
three groups of mice (mean ± SEM (counts) were: control, 49 ± 5; acute, 50 ± 4; 
subchronic, 57 ± 4) [F(2,20)=1.361; n.s.]. One-way ANOVA of the recognition index data 
showed a significant effect of treatment [F(2,26) = 8.26; p < 0.01]. Post-hoc Newman-
Keuls comparisons showed a significant decrease of the recognition index in the 
subchronic-treated mice compared to control (p < 0.01) and acute-treated (p < 0.01) 
mice (Fig.2b). The three groups of mice spent the same time exploring the objects on T1 
and T2. Thus, one-way ANOVA for T1 data showed non-significant differences on the 
total time of exploration (mean ± SEM (s) were: control, 31 ± 3;  acute, 38 ± 5;  
subchronic, 35 ± 6) [F(2,28)=0.530 ; n.s]. One-way ANOVA for T2 data showed non-
significant differences on the total time of exploration (mean ± SEM (s) were: control, 
33 ± 4; acute, 39 ± 5; subchronic, 34 ± 4) [F(2,28)=0.596 ; n.s].   
Effects of acute and subchronic PCP treatments in the tail suspension test 
Acute and subchronic PCP-treated mice showed higher immobility times than control 
mice in the tail suspension test. However, immobility differences among groups did not 
reach statistical significance ([F(2,28) = 2.61; n.s.], n.s., one-way ANOVA) (Fig. 3). 
Effects of acute and subchronic PCP treatments on the reversal of an egocentric 
response discrimination 
Before treatment, the three groups of mice did not differ in the total number of trials 
[F(2,26) = 0.54; n.s.] and incorrect trials [F(2,26) = 0.47; n.s.] to reach performance criterion 
on an egocentric response discrimination (Fig.4b). On the re-discrimination phase, one-
way ANOVA showed a significant effect of treatment on the total number of trials 
[F(2,26) = 4.58; p < 0.05] and incorrect trials [F(2,26) = 4.14; p < 0.05] to reach 
performance criterion. Post-hoc Newman-Keuls comparisons showed a significant 
difference between acute and control/subchronic groups (p < 0.05, in all cases) (Fig.4c). 
Non-significant differences between groups were observed during the reversal of the 
egocentric response discrimination. Thus, the three groups of mice did not differ in the 
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total number of trials [F(2,26) = 0.79; n.s.] and incorrect trials [F(2,26) = 1.06; n.s.] to reach 
criterion (Fig. 4d).  
Effects of acute and subchronic PCP treatments on mPFC serotonin and dopamine 
output 
Basal extracellular concentrations of 5-HT in dialysate samples of mPFC were: control, 
1.1 ± 0.2; acute, 1.5 ± 0.4; subchronic, 1.8 ± 0.5 expressed as fmol/60 µl. Non-
significant differences between treatments were found in basal 5-HT concentrations 
[F(2,9) = 0.80; n.s.] (Fig. 5a). The systemic administration of PCP (10 mg/kg, s.c.) 
increased the extracellular levels of 5-HT in mPFC similarly in the acute and subchronic 
groups (Fig. 5c). Thus, two-way repeated measures ANOVA showed a significant effect 
of treatment [F(2,16) = 6.08; p < 0.05], fraction [F(9,144) = 10.55; p < 0.01] and treatment x 
fraction interaction [F(18,144) = 3.32; p < 0.01]. Post-hoc Newman-Keuls test revealed 
significant differences between the acute and subchronic groups versus the control 
group (p < 0.05). 
Basal extracellular concentrations of DA in dialysate samples of mPFC were: 
control, 7.0 ± 0.4; acute, 5.7 ± 0.5; subchronic, 3.9 ± 0.3 expressed as fmol/30 µl. One-
way ANOVA showed a significant effect of treatment on basal DA concentrations 
[F(2,12) = 12.90; p < 0.01]. Basal DA concentrations in mPFC in the subchronic group 
were significantly lower than in the control and acute groups (p < 0.01, p < 0.05, 
respectively, post-hoc Newman-Keuls test) (Fig. 5b). The systemic administration of 
PCP (10 mg/kg, s.c.) increased the extracellular levels of DA in mPFC only in the 
subchronic group (Fig. 5d), indicating a sensitization of DA release after subchronic 
PCP, as observed with locomotor activity. Thus, two-way repeated measures ANOVA 
showed a significant effect of treatment [F(2,12) = 8.16; p < 0.01], fraction [F(11,132) = 
4.25; p < 0.01] and treatment x fraction interaction [F(22,132) = 4.15; p < 0.01]. Post-hoc 
Newman-Keuls test showed a significant difference between the subchronic group 
versus the control group (p < 0.01) and the acute group (p < 0.05). 
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Effects of acute and subchronic PCP treatments on tyrosine hydroxylase (TH) mRNA 
expression in the VTA 
TH mRNA expression in the VTA was markedly attenuated after subchronic (but not 
acute) PCP treatment. One-way ANOVA showed a significant effect of treatment [F(2,8) 
= 17.94; p < 0.01], with a significant decrease of TH mRNA expression in the 
subchronic group compared to the control (p < 0.01) and the acute (p < 0.05) groups 
(post-hoc Newman-Keuls test) (Fig. 6a, b). 
NeuN immunohistochemistry in the VTA 
The number of NeuN positive cells in the VTA of control and subchronic PCP-treated 
mice was similar. Thus, one-way ANOVA showed non-significant effects of treatment 
[F(1,6) = 2.42; n.s.], (Fig. 6c). 
c-fos mRNA expression after acute and subchronic PCP treatments 
Acute and subchronic PCP treatments induced a different pattern of c-fos expression in 
mice brains at both 1h and 96h post-treatment. At 1h, post-hoc Newman-Keuls test after 
significant main effect of the ANOVA showed that acute PCP treatment significantly 
increased c-fos expression (from anterior to posterior AP) in the medial prefrontal 
cortex (p <0.05), cingulate cortex (p < 0.01), dorsolateral striatum (p < 0.05), 
dorsomedial striatum (p < 0.05), piriform cortex (p < 0.01), ventral striatum (p < 0.01), 
retrosplenial cortex (p < 0.01), thalamus (p < 0.01), posterior hippocampus (p < 0.01), 
dorsal raphe (p < 0.01), and ectorhinal/perirhinal cortices (p < 0.01). In contrast, c-fos 
expression induced by subchronic PCP treatment was restricted to the restrosplenial 
cortex (p < 0.05), thalamus (p < 0.01), posterior hippocampus (p < 0.05) and the 
supramammilary nucleus (p < 0.01) (Fig. 7a).  
At 96h post-treatment, we observed differential changes (mainly decreases) in c-
fos expression due to the two PCP regimens. Acute PCP group significantly decreased 
c-fos mRNA expression in the dorsal raphe (p < 0.01). In contrast, subchronically PCP-
treated mice showed significantly decreased c-fos mRNA in the cingulate cortex (p < 
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0.01), dorsomedial striatum (p < 0.01), piriform cortex (p < 0.05), dorsal raphe (p < 
0.01), but an increased c-fos mRNA in the posterior hippocampus (p < 0.05) (Fig. 8).   
Discussion  
The present study investigated the behavioral manifestations produced by acute and 
subchronic PCP treatment in adult C57BL/6J mice, the long-term behavioral 
consequences of the two treatment regimens and some of their neurobiological 
substrates. Acute and subchronic PCP induced differential behavioral, neurochemical 
and cellular effects. In particular, subchronic PCP treatment evoked a sensitization of 
acute locomotor effects and working memory deficits. Moreover, subchronic PCP 
selectively disrupted dopaminergic neurotransmission in mPFC and produced a 
differential pattern c-fos expression, likely reflecting a differential involvement of some 
brain networks in both experimental conditions. Although the effects of subchronic PCP 
administration on behavioral variables have been previously reported (see Introduction), 
the present study shows a comprehensive view of PCP effects using behavioral, 
neurochemical and histological techniques. We are currently assessing the effects of the 
same treatment regime on brain oscillations in various areas of the behaving mice, in 
order to correlate behavioral changes with the activity of selected neuronal populations.  
Acute PCP treatment increased the locomotor activity of adult mice, an effect 
potentiated by the subchronic treatment. Behavioral sensitization is typically observed 
with dopaminergic drugs such as amphetamine and cocaine (Featherstone et al. 2007; 
Pierce and Kalivas 1997; Post and Rose 1976), and has also been observed in C57BL/6J 
and C57BL/6N mice after subchronic/chronic PCP treatment (Mouri et al. 2012; Xu and 
Domino 1994). The involvement of dopaminergic neurotransmission in the motor 
circuit of the basal ganglia is extensively documented (Alexander and Crutcher 1990; 
Gerfen 2000; Groenewegen 2003). An increased striatal DA release may partly mediate 
the hyperlocomotion induced by non-competitive NMDA-R antagonists, since PCP 
hyperlocomotor effects in mice can be antagonized by administration of DA receptor 
antagonists (Chartoff et al. 2005; Nagai et al. 2003). However, glutamatergic 
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mechanisms have also been described to contribute to NMDA-R mediated locomotor 
effects in dopamine-deficient mice (Chartoff et al. 2005) and after neurotoxic lesions of 
dopaminergic neurons (Lapin and Rogawski 1995). Likewise, the application of 
muscimol (GABAA agonist) in the anterior nucleus of the thalamus fully prevented the 
hyperlocomotion induced by the NMDA-R antagonist MK-801 (López-Hill and Scorza 
2012), thus counteracting the increased thalamic activity produced by NMDA-R 
blockade (Santana et al. 2011; Vaisanen et al. 2004). Hence, a recent report indicates 
that PCP mainly inhibits GABAergic neurons of the reticular nucleus of the thalamus, 
which provides feed-forward inhibition to the rest of thalamic nuclei (Troyano-
Rodríguez et al. 2014). This effect breaks the physiological balance between excitatory 
and inhibitory transmission in the thalamus and increases thalamic excitatory inputs to 
the neocortex.  Moreover, other anatomical data support a glutamatergic contribution, 
since basal ganglia receive dense glutamatergic inputs predominantly from prefrontal 
cortical areas, as well as from the hippocampus, periventricular thalamus, and amygdala 
(Carlsson and Carlsson 1990; Graybiel 1990; Phillipson and Griffiths 1985; Post and 
Rose 1976). Therefore, differential dopamine-glutamate interactions in the basal ganglia 
may contribute to acute PCP locomotor effects and as well as PCP-induced behavioral 
sensitization.   
We then explored whether acute and subchronic PCP treatment differentially 
activated c-fos expression in mice brain, as a surrogate marker of neuronal activity 
(Dragunow and Faull 1989;  Konkle and Bielajew 2004; Panagis et al. 1997; Sager et al. 
1988). Acute PCP induced a similar c-fos expression in mice than we previously 
described in rats using the same methodology (Kargieman et al. 2007; Santana et al. 
2011). Thus, at 1h post-treatment acute PCP (10 mg/kg) produced a significant increase 
of c-fos mRNA in many cortical areas such as mPFC, cingulate, retrosplenial, pyriform 
and ectorhinal/perirhinal cortices. Moreover, thalamic nuclei, dorsal raphe and to a 
lesser extent the posterior hippocampus also exhibited increased c-fos expression. After 
subchronic PCP most cortical areas activated by the acute PCP challenge returned to 
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control values. The retrosplenial cortex, thalamus and posterior hippocampus showed a 
significantly lower c-fos expression compared to the acute PCP group, yet still higher 
than controls. Moreover, the supramammillary nucleus (SuM) showed a very significant 
increase in c-fos expression after subchronic –but not acute- PCP. Interestingly, 
inactivation of the SuM has been shown to normalize both the hippocampal gamma 
waves and the hyperactivity induced by acute NMDA-R antagonists like MK-801 and 
ketamine in rats (Ma and Leung 2000, 2007). In our hands, the same subchronic PCP 
treatment regime also evoked a sustained hippocampal gamma oscillatory activity 
(Castañé, Lladó-Pelfort et al. unpublished observations). Thus, the activation of SuM 
produced by subchronic PCP may also contribute to PCP-induced locomotor 
sensitization in mice. 
In this study, differential long-term consequences of both acute and subchronic 
PCP treatment in mice were also examined. For this purpose, animals in withdrawal 
were exposed to several behavioral paradigms to evaluate cognitive function such as 
working memory and reversal learning, and depressive-like responses. We adapted the 
novel object recognition test paradigm to evaluate working memory function in mice by 
performing the assay in a T-maze and using an inter-trial interval (ITI) of low duration 
(3 minutes). Under these conditions, we observed that mice of the subchronic PCP 
group showed working memory deficits by means of decreased spontaneous alternation 
in the T-maze and decreased recognition index in the NOR test. The NOR paradigm has 
been previously used to demonstrate short- (1h ITI) and long-term (24h ITI) memory 
deficits after repeated PCP treatments in mice (Tanibuchi et al. 2009). However, this is 
the first time showing that working memory deficits of subchronic PCP-treated mice 
can be observable using this paradigm. Several neurotransmitters have been related to 
working memory, in particular dopamine (Landau et al. 2009; Vijayraghavan et al. 
2007; Williams and Goldman-Rakic 1995). Early work in rats and monkeys 
demonstrated that elevating or depleting DA in the PFC impaired spatial working 
memory performance (Simon, 1981; Bubser and Schmidt 1990; Murphy et al. 1996). In 
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agreement, we have shown a dopaminergic neurotransmission dysregulation in mPFC 
of subchronically PCP-treated mice. Concretely, we observed a decreased basal DA 
output in mPFC in microdyalisis experiments associated with a decreased tyrosine 
hydroxylase mRNA expression in the VTA. These changes were not due to neuronal 
loss in the VTA, since NeuN positive cells were similar in control and subchronic PCP 
groups. Moreover, the last PCP administration in the subchronic group produced a 
greater DA release in the mPFC, further suggesting that dopaminergic 
neurotransmission is particularly affected by the repeated PCP exposure. 
On the contrary, subchronic PCP treatment in mice had no observable effects on 
either discrimination learning or reversal of an egocentric response task. Reversal 
learning performance is dependent on prefrontal serotonin transmission (Boulougouris 
et al. 2008; Clarke et al. 2004, 2005). In accordance with the lack of effect of PCP on 
reversal learning, we observed comparable basal extracellular 5-HT levels in mPFC in 
the three groups of mice. To date, only another study has investigated the influence of 
subchronic PCP treatment in mice in a touch-screen based visual discrimination and 
reversal with no significant effects being observed (Brigman et al. 2009). However, 
studies performed in rats have led to impaired reversal learning abilities after subchronic 
PCP treatments (Jentsch and Taylor 2001), specially using operant settings (Idris et al. 
2010; Mc Lean et al. 2009, 2010, 2011). Recently, Fellini et al (2014) re-evaluated the 
effects of acute and sub-chronic PCP administration on reversal of a double visual 
discrimination task in rats, and found that acute but not sub-chronic PCP impaired 
reversal performance. Altogether, these data suggest that not all reversal learning tasks 
can be considered equivalent. The nature of stimuli used, the duration 
treatment/withdrawal and other procedural particularities (pre-training, operant/not 
operant task, re-discrimination) may engage different cognitive processes. Therefore, 
special attention should be put on designing and evaluating reversal learning abilities in 
rodents in order to clarify the impact of PCP treatments.  
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In order to investigate differential effects of acute and subchronic PCP on 
negative symptoms, we performed the tail suspension test on WD7. Both acute and 
subchronic PCP-treated mice showed increased immobility scores, however these 
effects did not reached statistically significance. Recently, Mouri and collaborators 
(2012) have described strain differences specially affecting chronic PCP-induced 
immobility responses in the forced swimming test. These authors described that 
immobility responses are less intense and durable in mice with C57BL/6J background 
compared to ddY or C57BL/6N, lasting no more than three days after finishing the 
chronic PCP treatment. Previous and present findings suggest that depressive-like 
effects induced by PCP treatments are not enduring, and mice with a C57BL/6J genetic 
background should not be used to reveal depressive-like responses of PCP treatments in 
the tail suspension and forced swimming tests at very long times.   
Finally, we determined the expression of c-fos mRNA at WD4 to investigate 
residual (drug-free) brain activity changes due to acute and subchronic PCP treatments 
that may account for the behavioral effects. Basal c-fos mRNA expression was higher in 
the posterior hippocampus, and lower in the cingulate and pyriform cortices, 
dorsomedial striatum and dorsal raphe in the subchronic group of mice. Acute PCP also 
decreased basal c-fos expression in the dorsal raphe at WD4, suggesting a residual effect 
on brain activity in this area due to both PCP regimens that may relevant to depressive-
like responses. 
In summary, the present study shows that acute and subchronic PCP 
administration differently affects neuronal activity in brain regions relevant to 
schizophrenia, which could account for their different behavioral effects. In particular,   
subchronic –but not acute- PCP evoked a locomotor sensitization and induced working 
memory deficits which may be partly accounted for by activity changes in several brain 
areas, including a reduced basal dopaminergic function and an increased activity of 
thalamocortical networks, among others.  
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Figure captions 
Figure 1. Locomotor activity measurements (90 min) were performed on day 1 (D1) 
and day 12 (D12) and started 10 min after drug administration. Data are expressed as 
mean ± SEM (n = 6-8 mice/group) of distance moved (cm) in 5 min intervals (a) or total 
distance moved in 90 min (b). A single administration of PCP (10 mg/kg, s.c.) increased 
locomotor activity as shown in the subchronic group on D1and the acute group on D12. 
Repeated PCP administration (10 mg/kg, s.c., 10 days) produced a sensitization of acute 
locomotor effects (D12). * p < 0.05, ** p < 0.01 vs control; # p < 0.05, ## p < 0.01 vs 
acute (post-hoc Newman-Keuls).  
Figure 2.  Mean ± SEM of percentage of alternation in a T-maze (a) and recognition 
index (RI) (b). Spontaneous alternation was evaluated on withdrawal day 4 (WD4). 
Mice of the subchronic PCP group exhibited a significant decrease of percentage of 
alternations (n = 6-8/group). Novel object recognition (NOR) test was performed in 
withdrawal day 5 (WD5). A 10 min (Trial 1)-3 min (Inter trial interval)-10 min (Trial 2) 
procedure was used to evaluate working memory in the NOR. Mice of the subchronic 
group showed RI values consistent with no memory retention of the familiar object. * p 
< 0.05, ** p < 0.01 vs control; # p < 0.05, ## p < 0.01 vs acute (post-hoc Newman-
Keuls) (n =8-11 mice/group).  
Figure 3.  Mean ± SEM of immobility time (s) in the tail suspension test (n = 8-
12/group). The test was performed at withdrawal day 7 (WD7).  
Figure 4. Schematic representation of the behavioral training and testing protocol (a). 
Data are expressed as mean ± SEM of total trials to criterion (TT), and incorrect trials to 
criterion (IT) in the discrimination phase (b), re-discrimination phase (c), and reversal 
phase (d).  * p < 0.05 vs control; # p < 0.05 vs subchronic (post-hoc Newman-Keuls) (n 
=5-12 mice/group).  
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Figure 5.  Basal extracellular levels of 5-HT (a) and DA (b) in mPFC of mice of the 
three groups of treatment. Data are expressed as mean ± SEM of four basal samples. 
Effects of the systemic acute and subchronic PCP administration (10 mg/kg, s.c.) on 
dialysate 5-HT (c) and DA (d) concentrations in the mPFC of mice. Data are expressed 
as percentages of pretreatment values and are given as mean ± SEM (5–9 mice/group).  
* p < 0.05,  ** p < 0.01 vs control; # p < 0.05 vs acute (post-hoc Newman-Keuls). 
Figure 6. Tyrosine hydroxylase mRNA expression in the ventral tegmental area (VTA). 
(a) Bar graphs showing mean ± SEM of optical density (arbitrary units) in the three 
experimental groups of mice (n=3-4 mice/group). (b) Representative autoradiograms 
showing the expression of tyrosine hydroxylase in coronal sections of VTA (AP in mm: 
-3.08). (c) Mean ± SEM of NeuN positive cells/µm
2
 in the VTA (n=3-4 mice/group). 
Figure 7.  c-fos mRNA expression in mice brain coronal sections after acute and 
subchronic PCP treatments. Mice were sacrificed 1h post-treatment. (a) Representative 
photographs of c-fos expression at different AP coordinates (from Bregma in mm): 
1.18, -1.58 and -3.08 in the different experimental groups. (b) Bar graphs showing mean 
± SEM of optical density (arbitrary units) in the three experimental groups of mice (n=3 
mice/group). * p < 0.05,  ** p < 0.01 vs control; # p < 0.05, ##  p < 0.01  vs acute (post-
hoc Newman-Keuls). 
Figure 8. c-fos mRNA expression in mice brain coronal sections after acute and 
subchronic PCP treatments. Mice were sacrificed at 96h post-treatment. Data are 
expresses as mean ± SEM of optical density (arbitrary units) in the three experimental 
groups of mice (n=3/group). * p < 0.05,  ** p < 0.01 vs control; # p < 0.05 vs acute 
(post-hoc Newman-Keuls).  
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Figure 1. Locomotor activity measurements (90 min) were performed on day 1 (D1) and day 12 (D12) and 
started 10 min after drug administration. Data are expressed as mean ± SEM (n = 6-8 mice/group) of 
distance moved (cm) in 5 min intervals (a) or total distance moved in 90 min (b). A single administration of 
PCP (10 mg/kg, s.c.) increased locomotor activity as shown in the subchronic group on D1and the acute 
group on D12. Repeated PCP administration (10 mg/kg, s.c., 10 days) produced a sensitization of acute 
locomotor effects (D12). * p < 0.05, ** p < 0.01 vs control; # p < 0.05, ## p < 0.01 vs acute (post-hoc 
Newman-Keuls).  
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Figure 2.  Mean ± SEM of percentage of alternation in a T-maze (a) and recognition index (RI) (b). 
Spontaneous alternation was evaluated on withdrawal day 4 (WD4). Mice of the subchronic PCP group 
exhibited a significant decrease of percentage of alternations (n = 6-8/group). Novel object recognition 
(NOR) test was performed in withdrawal day 5 (WD5). A 10 min (Trial 1)-3 min (Inter trial interval)-10 min 
(Trial 2) procedure was used to evaluate working memory in the NOR. Mice of the subchronic group showed 
RI values consistent with no memory retention of the familiar object. * p < 0.05, ** p < 0.01 vs control; # 
p < 0.05, ## p < 0.01 vs acute (post-hoc Newman-Keuls) (n =8-11 mice/group).  
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Figure 3.  Mean ± SEM of immobility time (s) in the tail suspension test (n = 8-12/group). The test was 
performed at withdrawal day 7 (WD7).  
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Figure 4. Schematic representation of the behavioral training and testing protocol (a). Data are expressed as 
mean ± SEM of total trials to criterion (TT), and incorrect trials to criterion (IT) in the discrimination phase 
(b), re-discrimination phase (c), and reversal phase (d).  * p < 0.05 vs control; # p < 0.05 vs subchronic 
(post-hoc Newman-Keuls) (n =5-12 mice/group).  
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Figure 5.  Basal extracellular levels of 5-HT (a) and DA (b) in mPFC of mice of the three groups of 
treatment. Data are expressed as mean ± SEM of four basal samples. Effects of the systemic acute and 
subchronic PCP administration (10 mg/kg, s.c.) on dialysate 5-HT (c) and DA (d) concentrations in the mPFC 
of mice. Data are expressed as percentages of pretreatment values and are given as mean ± SEM (5–9 
mice/group).  * p < 0.05,  ** p < 0.01 vs control; # p < 0.05 vs acute (post-hoc Newman-Keuls).  
124x79mm (300 x 300 DPI)  
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Figure 6. Tyrosine hydroxylase mRNA expression in the ventral tegmental area (VTA). (a) Bar graphs 
showing mean ± SEM of optical density (arbitrary units) in the three experimental groups of mice (n=3-4 
mice/group). (b) Representative autoradiograms showing the expression of tyrosine hydroxylase in coronal 
sections of VTA (AP in mm: -3.08). (c) Mean ± SEM of NeuN positive cells/µm2 in the VTA (n=3-4 
mice/group).  
170x46mm (300 x 300 DPI)  
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Figure 7.  c-fos mRNA expression in mice brain coronal sections after acute and subchronic PCP treatments. 
Mice were sacrificed 1h post-treatment. (a) Representative photographs of c-fos expression at different AP 
coordinates (from Bregma in mm): 1.18, -1.58 and -3.08 in the different experimental groups. (b) Bar 
graphs showing mean ± SEM of optical density (arbitrary units) in the three experimental groups of mice 
(n=3 mice/group). * p < 0.05,  ** p < 0.01 vs control; # p < 0.05, ##  p < 0.01  vs acute (post-hoc 
Newman-Keuls).  
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Figure 8. c-fos mRNA expression in mice brain coronal sections after acute and subchronic PCP treatments. 
Mice were sacrificed at 96h post-treatment. Data are expresses as mean ± SEM of optical density (arbitrary 
units) in the three experimental groups of mice (n=3/group). * p < 0.05,  ** p < 0.01 vs control; # p < 
0.05 vs acute (post-hoc Newman-Keuls).  
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